Evidence map›Paper›PMID 22621626›Full record

Trial reportThe New England journal of medicine2012

Aspirin for preventing the recurrence of venous thromboembolism.

Cecilia Becattini, Giancarlo Agnelli, Alessandro Schenone, Sabine Eichinger, Eugenio Bucherini, Mauro Silingardi, Marina Bianchi, Marco Moia, Walter Ageno, Maria Rita Vandelli and 3 more

Erratum issued 3 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The New England journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 173 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 17 pooled it
49.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00222677 phase2 / phase3unknown statusnot on this map

Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.

TypeinterventionalSponsorUniversity Of PerugiaRan2004Enrolled70ConditionsVenous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism, AtherosclerosisArmsaspirin
NCT04445623 phase3unknown statusnot on this mapstarted 2020, after this paper: background citation

Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients

TypeinterventionalSponsorAzienda Ospedaliera Universitaria Integrata VeronaRan2020 to 2021Enrolled128ConditionsCOVID19, ThrombosisArmsPrasugrel Hydrochloride 10 MG Oral Tablet, Placebo
NCT04808895 phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)

TypeinterventionalSponsorAzienda Ospedaliera Universitaria Integrata VeronaRan2021 to 2021Enrolled204ConditionsCOVID-19, Thrombosis PulmonaryArmsAcetylsalicylic acid, Placebo
3 · Its place in the literature

Who cites it

173 citing papers in PubMed, 17 syntheses or guidelines pooled it, 617 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Antiplatelet agents for the treatment of deep venous thrombosis.The Cochrane database of systematic reviews · 2022
    Pooled it
  6. Guideline
  7. Guideline
  8. Pooled it
  9. Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2018
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Trial

113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 2 countries.

Cecilia BecattiniDivision of Internal and Cardiovascular Medicine and Stroke Unit, Department of Internal Medicine, University of Perugia, Perugia, Italy. cecilia.becattini@unipg.it
Giancarlo Agnelli
Alessandro Schenone
Sabine Eichinger
Eugenio Bucherini
Mauro Silingardi
Marina Bianchi
Marco Moia
Walter Ageno
Maria Rita Vandelli
Elvira Grandone
Paolo Prandoni
WARFASA Investigators
University of Perugia · ITCasa Sollievo della Sofferenza · ITEnte Ospedaliero Ospedali Galliera · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITMedical University of Vienna · ATOspedale per gli Infermi · ITOspedale Valduce · ITSanta Maria Nuova Hospital · ITUniversity of Insubria · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbout 20% of patients with unprovoked venous thromboembolism have a recurrence within 2 years after the withdrawal of oral anticoagulant therapy. Extending anticoagulation prevents recurrences but is associated with increased bleeding. The benefit of aspirin for the prevention of recurrent venous thromboembolism is unknown.

methodsIn this multicenter, investigator-initiated, double-blind study, patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment were randomly assigned to aspirin, 100 mg daily, or placebo for 2 years, with the option of extending the study treatment. The primary efficacy outcome was recurrence of venous thromboembolism, and major bleeding was the primary safety outcome.

resultsVenous thromboembolism recurred in 28 of the 205 patients who received aspirin and in 43 of the 197 patients who received placebo (6.6% vs. 11.2% per year; hazard ratio, 0.58; 95% confidence interval [CI], 0.36 to 0.93) (median study period, 24.6 months). During a median treatment period of 23.9 months, 23 patients taking aspirin and 39 taking placebo had a recurrence (5.9% vs. 11.0% per year; hazard ratio, 0.55; 95% CI, 0.33 to 0.92). One patient in each treatment group had a major bleeding episode. Adverse events were similar in the two groups.

conclusionsAspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding. (Funded by the University of Perugia and others; WARFASA ClinicalTrials.gov number, NCT00222677.).

Indexed as

AgedAnticoagulantsAspirinDouble-Blind MethodFemaleFollow-Up StudiesHemorrhageHumansMaleMiddle AgedPlatelet Aggregation InhibitorsPulmonary EmbolismSecondary PreventionVenous ThromboembolismVenous ThrombosisVitamin KAnticoagulantsAspirinPlatelet Aggregation InhibitorsVitamin K

Identifiers

PMID22621626
OpenAlexW1975990989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.